RELMADA THERAPEUTICS, INC. Research and Development Expense
RELMADA THERAPEUTICS, INC. (RLMD) reported Research and Development Expense of $8.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $8.39M, a 197.72% increase year-over-year.
- RELMADA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $8.09M, a 32.33% decline year-over-year.
- RELMADA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $8.07M, a 26.61% decline year-over-year.
- RELMADA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $4.04M, a 63.80% decline year-over-year.
- RELMADA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $26.88M, a 41.79% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $46.18M, a 15.75% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $54.81M, a 51.64% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $113.32M, a 25.05% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 115 month | Research and Development Expense 118 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.39M 10-Q · filed 2026-08-06 | $16.48M 10-Q · filed 2026-08-06 | $24.55M derived: sum of 3 quarters · filed 2026-08-06 | $28.59M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2026-03-31 | $8.09M 10-Q · filed 2026-05-12 | $16.16M derived: sum of 2 quarters · filed 2026-05-12 | $20.20M derived: sum of 3 quarters · filed 2026-05-12 | $23.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-12-31 | $8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $12.11M derived: sum of 2 quarters · filed 2026-03-19 | $14.93M derived: sum of 3 quarters · filed 2026-08-06 | $26.88M 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $4.04M 10-Q · filed 2025-11-13 | $6.86M derived: sum of 2 quarters · filed 2026-08-06 | $18.81M 10-Q · filed 2025-11-13 | $29.81M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-06-30 | $2.82M 10-Q · filed 2026-08-06 | $14.77M 10-Q · filed 2026-08-06 | $25.77M derived: sum of 3 quarters · filed 2026-08-06 | $36.92M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-03-31 | $11.95M 10-Q · filed 2026-05-12 | $22.95M derived: sum of 2 quarters · filed 2026-05-12 | $34.10M derived: sum of 3 quarters · filed 2026-05-12 | $44.82M derived: sum of 4 quarters · filed 2026-05-12 | ||||||
| 2024-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $22.15M derived: sum of 2 quarters · filed 2026-03-19 | $32.87M derived: sum of 3 quarters · filed 2026-03-19 | $46.18M 10-K · filed 2026-03-19 | ||||||
| 2024-09-30 | $11.15M 10-Q · filed 2025-11-13 | $21.87M derived: sum of 2 quarters · filed 2025-11-13 | $35.18M 10-Q · filed 2025-11-13 | $49.93M derived: sum of 4 quarters · filed 2025-11-13 | ||||||
| 2024-06-30 | $10.72M 10-Q · filed 2025-08-07 | $24.03M 10-Q · filed 2025-08-07 | $38.78M derived: sum of 3 quarters · filed 2025-08-07 | $49.23M derived: sum of 4 quarters · filed 2025-08-07 | ||||||
| 2024-03-31 | $13.31M 10-Q · filed 2025-05-12 | $28.06M derived: sum of 2 quarters · filed 2025-05-12 | $38.51M derived: sum of 3 quarters · filed 2025-05-12 | $52.25M derived: sum of 4 quarters · filed 2025-05-12 | ||||||
| 2023-12-31 | $14.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $25.21M derived: sum of 2 quarters · filed 2025-03-27 | $38.95M derived: sum of 3 quarters · filed 2025-03-27 | $54.81M 10-K · filed 2025-03-27 | ||||||
| 2023-09-30 | $10.45M 10-Q · filed 2024-11-07 | $24.19M derived: sum of 2 quarters · filed 2024-11-07 | $40.06M 10-Q · filed 2024-11-07 | $66.92M derived: sum of 4 quarters · filed 2024-11-07 | ||||||
| 2023-06-30 | $13.74M 10-Q · filed 2024-08-07 | $29.60M 10-Q · filed 2024-08-07 | $56.47M derived: sum of 3 quarters · filed 2024-08-07 | $87.00M derived: sum of 4 quarters · filed 2024-08-07 | ||||||
| 2023-03-31 | $15.86M 10-Q · filed 2024-05-08 | $42.73M derived: sum of 2 quarters · filed 2024-05-08 | $73.26M derived: sum of 3 quarters · filed 2024-05-08 | $104.17M derived: sum of 4 quarters · filed 2024-05-08 | ||||||
| 2022-12-31 | $26.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $57.40M derived: sum of 2 quarters · filed 2024-03-19 | $88.31M derived: sum of 3 quarters · filed 2024-03-19 | $113.32M 10-K · filed 2024-03-19 | ||||||
| 2022-09-30 | $30.53M 10-Q · filed 2023-11-08 | $61.44M derived: sum of 2 quarters · filed 2023-11-08 | $86.45M 10-Q · filed 2023-11-08 | $111.73M derived: sum of 4 quarters · filed 2023-11-08 | ||||||
| 2022-06-30 | $30.91M 10-Q · filed 2023-08-08 | $55.93M 10-Q · filed 2023-08-08 | $81.20M derived: sum of 3 quarters · filed 2023-08-08 | $115.19M derived: sum of 4 quarters · filed 2023-08-08 | ||||||
| 2022-03-31 | $25.01M 10-Q · filed 2022-05-05 | $50.29M derived: sum of 2 quarters · filed 2023-03-23 | $84.28M derived: sum of 3 quarters · filed 2023-03-23 | $101.61M derived: sum of 4 quarters · filed 2023-03-23 | ||||||
| 2021-12-31 | $25.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $59.27M derived: sum of 2 quarters · filed 2023-03-23 | $76.60M derived: sum of 3 quarters · filed 2023-03-23 | $90.62M 10-K · filed 2023-03-23 | ||||||
| 2021-09-30 | $33.99M 10-Q · filed 2022-11-10 | $51.33M derived: sum of 2 quarters · filed 2022-11-10 | $65.35M 10-Q · filed 2022-11-10 | $80.25M derived: sum of 4 quarters · filed 2022-11-10 | ||||||
| 2021-06-30 | $17.33M 10-Q · filed 2022-08-11 | $31.35M 10-Q · filed 2022-08-11 | $46.26M derived: sum of 3 quarters · filed 2022-08-11 | $57.49M derived: sum of 4 quarters · filed 2022-08-11 | ||||||
| 2021-03-31 | $14.02M 10-Q · filed 2022-05-05 | $28.93M derived: sum of 2 quarters · filed 2022-05-05 | $40.16M derived: sum of 3 quarters · filed 2022-05-05 | $45.49M derived: sum of 4 quarters · filed 2022-05-05 | ||||||
| 2020-12-31 | $14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $26.14M derived: sum of 2 quarters · filed 2022-03-25 | $31.46M derived: sum of 3 quarters · filed 2022-03-25 | $35.97M 10-K · filed 2022-03-25 | ||||||
| 2020-09-30 | $11.24M 10-Q · filed 2021-11-12 | $16.56M derived: sum of 2 quarters · filed 2021-11-12 | $21.07M 10-Q · filed 2021-11-12 | $22.70M derived: sum of 4 quarters · filed 2021-11-12 | ||||||
| 2020-06-30 | $5.32M 10-Q · filed 2021-08-10 | $9.83M 10-Q · filed 2021-08-10 | $11.46M derived: sum of 3 quarters · filed 2021-08-10 | $13.35M derived: sum of 4 quarters · filed 2021-08-10 | ||||||
| 2020-03-31 | $4.51M 10-Q · filed 2021-05-12 | $6.13M derived: sum of 2 quarters · filed 2021-05-12 | $8.02M derived: sum of 3 quarters · filed 2021-05-12 | $11.09M derived: sum of 4 quarters · filed 2021-05-12 | ||||||
| 2019-12-31 | $1.63M derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-24 | $3.51M 10-K · filed 2021-03-24 | $6.58M derived: sum of 3 quarters · filed 2021-03-24 | $7.86M 10-K · filed 2021-03-24 | ||||||
| 2019-09-30 | $1.89M 10-Q · filed 2020-11-12 | $4.96M derived: sum of 2 quarters · filed 2020-11-12 | $6.23M 10-Q · filed 2020-11-12 | $7.49M derived: sum of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | $3.07M 10-Q · filed 2020-08-12 | $4.35M 10-Q · filed 2020-08-12 | $5.60M derived: sum of 3 quarters · filed 2020-08-12 | $7.02M 10-K · filed 2021-03-24 | ||||||
| 2019-03-31 | $1.28M 10-Q · filed 2020-05-15 | $2.53M derived: sum of 2 quarters · filed 2020-05-15 | $3.95M 10-Q · filed 2019-05-15 | $4.91M derived: sum of 4 quarters · filed 2020-05-15 | ||||||
| 2018-12-31 | $1.26M 10-Q · filed 2019-02-13 | $2.68M 10-KT · filed 2020-03-26 | $3.64M derived: sum of 3 quarters · filed 2020-03-26 | $5.31M derived: sum of 4 quarters · filed 2020-03-26 | ||||||
| 2018-09-30 | $1.42M 10-Q · filed 2019-11-13 | $2.38M derived: sum of 2 quarters · filed 2020-03-26 | $4.05M derived: sum of 3 quarters · filed 2020-03-26 | $4.20M derived: sum of 4 quarters · filed 2020-03-26 | ||||||
| 2018-06-30 | $959.25K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $2.63M derived: sum of 2 quarters · filed 2020-03-26 | $2.78M derived: sum of 3 quarters · filed 2020-03-26 | $2.94M 10-KT · filed 2020-03-26 | ||||||
| 2018-03-31 | $1.67M 10-Q · filed 2019-05-15 | $1.82M derived: sum of 2 quarters · filed 2019-05-15 | $1.98M 10-Q · filed 2019-05-15 | $2.17M derived: sum of 4 quarters · filed 2019-05-15 | ||||||
| 2017-12-31 | $150.72K 10-Q · filed 2019-02-13 | $316.47K 10-Q · filed 2019-02-13 | $501.02K derived: sum of 3 quarters · filed 2019-02-13 | $991.71K derived: sum of 4 quarters · filed 2019-02-13 | ||||||
| 2017-09-30 | $165.75K 10-Q · filed 2018-11-13 | $350.30K derived: sum of 2 quarters · filed 2018-11-13 | $840.99K derived: sum of 3 quarters · filed 2018-11-13 | $1.10M derived: sum of 4 quarters · filed 2018-11-13 | ||||||
| 2017-06-30 | $184.55K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28 | $675.24K derived: sum of 2 quarters · filed 2018-09-28 | $929.35K derived: sum of 3 quarters · filed 2018-09-28 | $1.29M 10-K · filed 2018-09-28 | ||||||
| 2017-03-31 | $490.69K 10-Q · filed 2018-05-14 | $744.80K derived: sum of 2 quarters · filed 2018-05-14 | $1.11M 10-Q · filed 2018-05-14 | $1.72M derived: sum of 4 quarters · filed 2018-05-14 | ||||||
| 2016-12-31 | $254.10K 10-Q · filed 2018-02-12 | $618.26K 10-Q · filed 2018-02-12 | $1.23M derived: sum of 3 quarters · filed 2018-02-12 | $1.84M derived: sum of 4 quarters · filed 2018-02-12 | ||||||
| 2016-09-30 | $364.15K 10-Q · filed 2017-11-14 | $977.90K derived: sum of 2 quarters · filed 2017-11-14 | $1.59M derived: sum of 3 quarters · filed 2017-11-14 | $3.71M derived: sum of 4 quarters · filed 2017-11-14 | ||||||
| 2016-06-30 | $613.75K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | $1.22M derived: sum of 2 quarters · filed 2017-09-28 | $3.34M derived: sum of 3 quarters · filed 2017-09-28 | $6.21M 10-K · filed 2017-09-28 | ||||||
| 2016-03-31 | $609.12K 10-Q · filed 2017-05-15 | $2.73M derived: sum of 2 quarters · filed 2017-05-15 | $5.59M 10-Q · filed 2017-05-15 | $8.46M derived: sum of 4 quarters · filed 2017-05-15 | ||||||
| 2015-12-31 | $2.12M 10-Q · filed 2017-02-10 | $4.98M 10-Q · filed 2017-02-10 | $7.85M derived: sum of 3 quarters · filed 2017-02-10 | $10.12M derived: sum of 4 quarters · filed 2017-02-10 | ||||||
| 2015-09-30 | $2.87M 10-Q · filed 2016-11-10 | $5.73M derived: sum of 2 quarters · filed 2016-11-10 | $8.01M derived: sum of 3 quarters · filed 2016-11-10 | $10.10M derived: sum of 4 quarters · filed 2016-11-10 | ||||||
| 2015-06-30 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | $5.14M derived: sum of 2 quarters · filed 2016-09-09 | $7.23M derived: sum of 3 quarters · filed 2016-09-09 | $7.87M 10-K · filed 2016-09-09 | ||||||
| 2015-03-31 | $2.27M 10-Q · filed 2016-05-09 | -$2.27M 10-Q · filed 2015-05-15 | $4.37M derived: sum of 2 quarters · filed 2016-05-09 | $5.01M 10-Q · filed 2016-05-09 | -$5.01M 10-Q · filed 2015-05-15 | $6.14M derived: sum of 4 quarters · filed 2016-05-09 | ||||
| 2014-12-31 | $2.09M 10-Q · filed 2016-02-05 | -$2.09M 10-Q · filed 2015-02-13 | $2.81M 10-Q · filed 2016-02-05 | -$2.81M 10-Q · filed 2015-02-13 | $3.87M derived: sum of 3 quarters · filed 2016-02-05 | $3.65M derived: sum of 4 quarters · filed 2016-02-05 | ||||
| 2014-09-30 | $718.97K 10-Q · filed 2015-11-06 | -$718.97K 10-Q · filed 2014-11-07 | $1.77M derived: sum of 2 quarters · filed 2015-11-06 | $1.56M derived: sum of 3 quarters · filed 2015-11-06 | -$2.71M derived: sum of 4 quarters · filed 2015-11-06 | |||||
| 2014-06-30 | $1.06M derived: 10-K 6 month − 10-Q 3 month · filed 2015-09-11 | $839.96K 10-K · filed 2015-09-11 | -$839.96K 10-KT · filed 2014-09-09 | -$3.43M derived: sum of 3 quarters · filed 2015-09-11 | -$3.70M derived: sum of 4 quarters · filed 2015-09-11 | |||||
| 2014-03-31 | -$215.79K 10-Q · filed 2015-05-15 | -$4.48M derived: sum of 2 quarters · filed 2015-05-15 | -$4.76M 10-Q · filed 2015-05-15 | -$8.46M 8-K · filed 2014-05-27 | ||||||
| 2013-12-31 | -$4.27M 10-Q · filed 2015-02-13 | -$4.54M 10-Q · filed 2015-02-13 | $5.25M 10-K · filed 2015-09-11 | -$5.25M 8-K · filed 2014-05-27 | -$8.25M 8-K · filed 2014-05-27 | |||||
| 2013-09-30 | -$274.37K 10-Q · filed 2014-11-07 | |||||||||
| 2013-03-31 | -$337.84K 8-K · filed 2014-05-27 | |||||||||
| 2012-12-31 | -$667.47K 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |